New cancer drug enters first human testing
NCT ID NCT06331559
Summary
This early-stage trial tested a new drug called SIM0501, both alone and combined with an existing cancer drug (olaparib), in people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check the safety of the drug, see how the body processes it, and look for early signs that it might help shrink tumors. The study was designed for patients whose tumors have specific genetic changes (BRCAm, HRRm, or HRD).
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shandong Cancer Hospital
Jinan, Shandong, 250117, China
Conditions
Explore the condition pages connected to this study.